ReviewJournal of clinical and diagnostic research : JCDR2014
Ivacaftor: a novel mutation modulating drug.
Review in Journal of clinical and diagnostic research : JCDR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Ceragenins in Combination with Ivacaftor Prevent the Formation of Biofilm by Bacteria That Cause Rhinosinusitis.Pharmaceutics · 2025Article
- Injectable long-acting ivacaftor-loaded poly (lactide-co-glycolide) microparticle formulations for the treatment of cystic fibrosis: In vitro characterization and in vivo pharmacokinetics in mice.International journal of pharmaceutics · 2024Article
- Review
- Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells.PloS one · 2023Article
- Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis.Pediatric pulmonology · 2022Article
- CFTR function and clinical response to modulators parallel nasal epithelial organoid swelling.American journal of physiology. Lung cellular and molecular physiology · 2021Article
- Cystic fibrosis-related diabetes: The unmet need.World journal of diabetes · 2020Article
- Evidence for personalised medicine: mechanisms, correlation, and new kinds of black box.Theoretical medicine and bioethics · 2019Article
- Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique.Frontiers in pharmacology · 2018Review
- Nasospheroids permit measurements of CFTR-dependent fluid transport.JCI insight · 2017Article
- Barriers to inhaled gene therapy of obstructive lung diseases: A review.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Analyzing the Effects of a G137V Mutation in the FXN Gene.Frontiers in molecular neuroscience · 2015Article
- Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis-Related Diabetes.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis (CF) is multisystemic disorder presenting in newborn period to adulthood, predominantly affecting respiratory system. It is caused by mutation in CF transmembrane conductance regulator gene. ΔF508 is the most common mutation seen worldwide. Supportive management with bronchodilators, anti-inflammatory, mucolytics, antibiotics are the corner stone of therapy. Mutation specific drug, Ivacaftor, was recently approved USFDA in January 2012 for patients carrying G551D mutation. It is approved in patients who are six years and older in 150 mg twice daily dosing schedule with fat containing meals. It improves the lung function and other aspects of disease including weight gain. The side effects like upper respiratory infection, headache, rash, diarrhoea, stomach ache and dizziness are mild and self-limiting. This is excellent example of promise of personalised medicine - targeted drug that treat patients with specific genetic makeup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.